Prague, July 7, 2025 – The law firm ROWAN LEGAL acted as legal advisor in the successful completion of another investment round for the biotechnology company CasInvent Pharma. This strategic investment will enable the initiation of clinical development for innovative CK1 inhibitors, which represent a new direction in the treatment of resistant cancer diseases.
The investment confirms the growing trust of investors in top-notch biotechnological research conducted in the South Moravian Region and significantly strengthens the mission of CasInvent Pharma – to develop new generations of targeted therapies for patients with limited treatment options.
“We are proud to have been part of this important transaction and to support a Czech company with the potential to significantly impact global oncology research. At ROWAN LEGAL, we have a long-standing commitment to supporting innovative Czech companies on their path to international growth, particularly in the fields of biotechnology, startups, and venture capital investments,” said Jan Frey, Partner at ROWAN LEGAL. The transaction was further assisted by other office partner Jan Tomíšek and attorneys Tereza Jirásková and Kristýna Kupcová.
For more information contact:
Petr Podzimek
Head of PR & Marketing
ROWAN LEGAL
Phone: 725 032 147
Email: podzimek@rowan.legal
